Here’s the latest on RSV vaccines in Australia as of now.
Arexvy approved for adults 60 and older: Australia’s Therapeutic Goods Administration (TGA) approved Arexvy for Australians aged 60+, marking the first RSV vaccine approved in the country for this age group. Availability has been rolled out primarily through private channels, with supply and pricing details expected from health authorities soon after approval. This milestone followed U.S. approval and aligns with Australia’s interest in protecting older adults from severe RSV outcomes. [Source: Guardian article on TGA approval for Arexvy in Australia ][1]
Abrysvo and other RSV interventions: Australia’s immunisation framework includes Abrysvo (another RSV vaccine) and Beyfortus (nirsevimab) for infants and certain at-risk groups, with guidance published by state/territory health authorities and the Australian Immunisation Handbook. This reflects a broader strategy to protect both pregnant women and young children, alongside older adults. [Source: Health Victoria and Monash/other health resources summarizing RSV vaccine approvals and scheduling ][3][5]
Access in practice during 2024–2025: In 2024, RSV vaccines became available in the private market for eligible older adults, and state programs began offering monoclonal antibodies to infants in some jurisdictions. News coverage highlighted that access could vary by state and funding availability, with ongoing discussions about making vaccines more widely free or subsidised for high-risk groups. [Source: ABC News Australia coverage of vaccine availability for winter 2024, 9 News coverage on funding considerations ][7][3]
What to expect going forward: Australian health authorities have indicated further RSV vaccine approvals and program expansions (including maternal vaccination with Abrysvo in pregnancy) as the NIP evolves, with updates on supply, pricing, and eligibility expected from federal and state health departments. [Source: SEMPHN RSV resources and Victorian health page detailing current immunisation products and schedules ][4][5]
If you’d like, I can:
Welcome to South Eastern Melbourne Primary Health Network (SEMPHN). We fund health services across south eastern Melbourne and work with health professionals to improve health outcomes across the catchment.
www.semphn.org.auUp to date recommendations, vaccine schedules and resources on RSV (Respiratory syncytial virus) for immunisation providers.
www.health.vic.gov.auContagious respiratory disease can create more serious symptoms in people with low immunity
www.theguardian.comThe Therapeutic Goods Administration (TGA) has approved a vaccine against respiratory syncytial virus (RSV) in Australia for the first time. The shot, called Arexvy and manufactured by GSK, will be available by prescription to adults over 60.
www.monash.eduRSV vaccines are available for Australians for the first time this winter, but depending on what state you live in access may be limited. Linda Baumann battled the virus and knows just how fast it can…
www.abc.net.au